Board of Directors
Cathal Friel (aged 54) – Chairman
Cathal Friel has 30 plus years of corporate experience and is the Managing Director and founder of Raglan Capital. Cathal was a Co-founder and Director of Amryt Pharma plc, a leading European Orphan Drug Company listed on the London and Dublin Stock Exchanges. He is also Director and one of the founders of Open Orphan, was previously Executive Chairman and co-founder of Fastnet Oil & Gas plc and was one of the founding directors of Merrion Stockbrokers. Cathal has an MBA from the University of Ulster.
Anthony Richardson (aged 53) – Chief Executive Officer
Tony Richardson is a Fellow of the Chartered Association of Certified Accountants. He co-founded Alltracel Pharmaceuticals PLC in 1996 and acted as CFO for the company until 2004 at which stage he assumed the role of CEO. During his tenure as CEO Alltracel headcount increased from twenty to two hundred and fifty and revenues increased from €3 million to €33 million. Alltracel listed on AIM in 2001 and successfully used this platform to complete and integrate two acquisitions in the area of Oral Health before a trade sale in 2008 to Hemcon Medical Technologies Inc. Tony joined Venn Life Sciences in 2007 as Non-Executive Chairman. In 2010 he assumed the role of CEO and in that year Venn completed two acquisitions that provide the basis for the current business. He is an alumnus of Stanford University where he completed an executive program in Leadership for Growth.
Christian Milla (aged 55) – Chief Operational Officer
Christian Milla holds a PhD in Neuropharmacology from the University of Paris and has more than 20 years’ experience in the Drug Development and Clinical Trials Industry. Christian has also contributed to the foundation and development of several innovative start-up companies in the healthcare area. He joined Venn from from Oncodesign Biotechnology, a leader in preclinical evaluations for anticancer, based in France, where he was Chief Operating Officer. He was also a Board member of Cromsource, a provider of outsourced services to the pharmaceutical, biotechnology and medical device industries. From 2004 until 2007 Christian was CEO of OSMO Accovion SA, a niche Oncology Site Management and CRO. Prior to this he held roles with Parexel, Staticon International and Abbott Laboratories.
Michael Ryan (aged 60) – Senior Independent Director
Mike has a B.Eng. (Hons), Master Industrial Eng. (1st Hons), spent 7 years working with major OEMs in Ireland and has 4 years’ experience with the Irish Trade Board. He was a founding partner and major shareholder in Excal AB from 2000 until 2011. Mike headed a group of investors who bought Artema Medical AB in Stockholm, the global leaders in the development, supply and marketing of medical breathing gas analysers and related accessories. Mike is on the board of a number of other companies and in 2010 co-founded Irrus Investments, the first angel investment syndicate in Ireland.
Michael Ryan is Chairman of the Nomination Committee and is a member of the Remuneration Committee and the Audit & Risk Committee.
Brendan Buckley (aged 68) – Non-Executive Director
Prof Brendan Buckley, a medical graduate of University College Cork (UCC) and a doctoral graduate in Biochemistry of Oxford University, Brendan has over 30 years’ experience in clinical research. Brendan is a Director and one of the founders of Open Orphan as well as of a number of other developmental stage biopharma companies. He is also Adjunct Professor at University College Dublin and has published over 150 scientific papers. He was the Chief Medical Officer of ICON plc until 2017, prior to which he co-founded Firecrest Clinical, a company which focused on improving the performance of clinical trial sites. Brendan was a Director of the Health Products Regulatory Authority of Ireland between 2004 and 2011 and was a member of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) from 2000-2003 and the EMA Scientific Advisory Committee on Diabetes and Metabolism until 2011.